# Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?

> **NCT00732966** · NA · UNKNOWN · sponsor: **Assaf-Harofeh Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** losartan
- **DRUG:** valsartan

## Key facts

- **NCT ID:** NCT00732966
- **Lead sponsor:** Assaf-Harofeh Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-09
- **Primary completion:** 2009-09
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2008-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00732966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00732966, "Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00732966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*